Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives
نویسندگان
چکیده
منابع مشابه
Stimulating erythropoiesis: future perspectives.
The introduction of recombinant human erythropoietin (rHuEpo) nearly 20 years ago has revolutionised the management of patients with CKD, providing the opportunity for safe long-term anaemia correction without the attendant risks identified with blood products. Based on our expanding knowledge in this area, there are many exciting and innovative new approaches to anaemia correction that stand o...
متن کاملErythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.
Erythropoiesis-stimulating agents (ESA) used for the treatment of chemotherapy-induced anemia in cancer patients have been associated with adverse outcomes of enhanced tumor progression and impaired survival in a series of recent clinical trials. As clinical practice guidelines for ESA administration in cancer patients have evolved to improve safety, the mechanisms underlying the adverse outcom...
متن کاملPharmacovigilance in practice: erythropoiesis-stimulating agents
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other problems related to medical products after they have been licensed for marketing. The purpose of PV is to advance the safe use of marketed medical products. Regulatory agencies and license holders collaborate to collect data reported by health car...
متن کاملErythropoiesis stimulating agents: a personal journey.
I write this editorial in deference to the many experts who devote their careers to this important field. In this editorial, I simply report the journeyman route of a medical oncologist who is desperately trying to improve the outcomes of women suffering from breast cancer. At the end of the 1990s, there was much hope that erythropoie-sis stimulating agents (ESAs) would improve the survival of ...
متن کاملErythropoiesis stimulating agents: approaches to modulate activity
Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be required to achieve required hemoglobin levels. Therefore, a need was identified in some anemic pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2009
ISSN: 0007-1048,1365-2141
DOI: 10.1111/j.1365-2141.2009.07702.x